The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

https://doi.org/10.1016/j.bbrc.2021.09.023Get rights and content

Highlights

  • CT-P59 showed the antiviral effect but reduced susceptibility against authentic Gamma, Delta, Epsilon and Kappa variants in cell experiments.

  • CT-P59 showed neutralizing activity against pseudovirus variants: Gamma, Delta, Epsilon, Kappa, K417T, E484K, N501Y, L452R, T478K and P681H.

  • Clinically relevant dose of CT-P59 showed in vivo protection against Gamma and Delta variants in hACE2-expressing mice challenge experiments.

Abstract

The SARS-CoV-2 variant is rapidly spreading across the world and causes to resurge infections. We previously reported that CT-P59 presented its in vivo potency against Beta variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the antiviral effect of CT-P59 on Gamma, Delta and its associated variants (L452R). To tackle this question, we carried out cell tests and animal studies. CT-P59 showed neutralization against Gamma, Delta, Epsilon, and Kappa variants in cells, with reduced susceptibility. The mouse challenge experiments with Gamma and Delta variants substantiated in vivo potency of CT-P59 showing symptom remission and virus abrogation in the respiratory tract. Collectively, cell and animal studies showed that CT-P59 is effective against Gamma and Delta variants infection, hinting that CT-P59 has therapeutic potential for patients infected with Gamma, Delta and its associated variants.

Keywords

SARS-CoV-2 variant
Therapeutic antibody
CT-P59
Regdanvimab
Gamma
Delta

Cited by (0)

View Abstract